Best Semaglutide Dose for Weight Loss

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The optimal semaglutide dose for weight loss typically ranges from 0.5 mg to 2.4 mg weekly, administered as a subcutaneous injection. Clinical trials show most patients titrate gradually over 16–20 weeks, with dose increases occurring every 4 weeks to minimize gastrointestinal side effects and assess individual tolerance.

Finding the right dose is not a one-size-fits-all decision. Response varies significantly between individuals due to metabolic differences, baseline insulin sensitivity, and genetic predispositions in GLP-1 receptor signaling. Understanding these factors—alongside clinical guidance—supports more informed conversations about your treatment plan.

How Semaglutide Dosing Works: The Titration Protocol

Semaglutide dosing follows a structured titration schedule to balance efficacy with tolerability. Treatment typically begins at 0.25 mg weekly, increasing by 0.25 mg every 4 weeks until reaching a maintenance dose. Most patients experience meaningful weight loss at 1.0–2.4 mg weekly, though individual tolerance varies.

The gradual approach reduces nausea, vomiting, and other gastrointestinal effects that occur with rapid dose escalation. Some patients maintain steady results at lower doses (0.5–1.0 mg), while others require higher doses for optimal weight loss. Your healthcare provider adjusts pacing based on your response and side effect profile.

Clinical Evidence: What Weight Loss Data Shows at Each Dose Level

Clinical trials demonstrate dose-dependent weight loss across semaglutide dosing ranges. The STEP trial series (the landmark weight loss studies) tracked outcomes at multiple doses, revealing consistent efficacy patterns and informing current prescribing practices. Below is a summary of representative data from these pivotal studies.

Maintenance Dose (mg/week)	Average Weight Loss	Study Population	Key Finding
0.5	3–5% body weight	Titration phase participants	Minimal but measurable; often used as starting reference point
1.0	6–8% body weight	STEP trial participants	Moderate efficacy; many patients stabilize here
1.7	10–12% body weight	STEP 3 trial (2,000+ patients)	Clinically significant loss; well-tolerated in most
2.4	12–15% body weight	STEP trials (highest dose studied)	Maximum efficacy in trials; individual variation remains high

Why Individual Semaglutide Response Varies: Genetic and Metabolic Factors

Genetic predispositions in GLP-1 receptor pathways, appetite regulation, and fat metabolism influence how individuals respond to semaglutide. Variants in related metabolic genes affect receptor sensitivity and signaling efficiency, meaning two patients at the same dose may experience different weight loss outcomes.

Baseline metabolic state, insulin resistance, fasting glucose, and gut hormonal profiles also shape semaglutide efficacy. Individuals with higher baseline insulin levels may require different titration pacing than those with insulin-sensitive profiles. These contextual factors are important for your provider to consider when personalizing your dose pathway.

Safety Considerations and Who Should Start Lower vs. Higher Dosing

Patients with a history of severe gastrointestinal conditions, pancreatitis, or medullary thyroid cancer should avoid semaglutide entirely. Those with diabetic retinopathy, significant renal impairment, or borderline hypotension may benefit from slower titration or lower maintenance doses. Your provider evaluates baseline health status before recommending a starting dose.

Starting at 0.25 mg and titrating gradually is the standard approach because it allows early detection of intolerance and reduces dropout due to side effects. Some patients achieve meaningful weight loss at 0.5–1.0 mg and discontinue titration there. Others require 2.4 mg for optimal results. Personalization, not a predetermined target dose, is the evidence-based standard.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key GLP-1 and appetite-regulation pathways (GIPR rs1800437, MC4R rs17782313, FTO rs9939609) that may help provide context for individual dose response variability. These findings should be interpreted with your healthcare provider as part of a comprehensive assessment—they inform conversation, not prescribing decisions.

The genetic test identifies whether you carry variants associated with heightened or reduced GLP-1 receptor sensitivity and metabolic efficiency. This information may suggest whether you are predisposed to respond at lower doses or potentially require higher maintenance doses for optimal effect. Genetic predisposition is not destiny; environmental factors, adherence, and individual physiology remain central.

Understanding your genetic predispositions can support a more informed discussion with your provider about realistic expectations, potential titration pace, and what dose range may best align with your metabolic profile. This personalized context—combined with clinical evidence and your real-world response—creates a framework for smarter dose optimization.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does this article name a single best dose?

No, and it says so directly: personalization rather than a predetermined target dose is what it calls the evidence-based standard. It describes a range in which most people find meaningful effect, notes some stabilize at the lower end and stop there, and leaves the decision with the prescriber. The article treats the question in its own title as slightly wrong-headed.

What titration cadence does the article describe?

Increases roughly every four weeks across a 16 to 20 week period, starting at the lowest weekly strength. The way it describes the size of each step does not match the sequence its own table lists, so the two passages are not fully consistent. Actual pacing comes from the prescriber and the dispensing label, which the article says varies with tolerance.

How does the table relate dose level to weight loss?

It shows a dose-dependent pattern, moving from a few percent of body weight at the lowest maintenance level up to the low-to-mid teens at the highest studied dose. One row attributes its figure to a specific STEP trial with a participant count that does not match that study, so the sourcing is unreliable even though the overall direction matches published semaglutide research.

Who does the article say should avoid semaglutide, and who should go slowly?

It says people with a history of severe gastrointestinal conditions, pancreatitis, or medullary thyroid cancer should avoid it entirely. A second group, those with diabetic retinopathy, significant renal impairment, or borderline hypotension, may do better with slower titration or a lower maintenance level. Baseline health status is what the article says determines which category someone falls into.

Why does the article defend starting at the lowest strength?

Two reasons: it allows early detection of intolerance, and it reduces dropout caused by side effects. The article ties rapid escalation to nausea and vomiting, and argues the gradual approach preserves efficacy while making the treatment survivable. It notes some people never need to go past the middle of the range to get the result they wanted.

Related Reading

• Semaglutide For Weight Loss 2
• Semaglutide Tablets For Weight Loss
• Semaglutide Pills For Weight Loss
• Oral Semaglutide Weight Loss

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.